
ADC Therapeutics SA ADCT
$ 1.33
-0.75%
Country |
|
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NYSE |
Shares |
127 M |
Market Cap[1] |
$ 169 M |
EBITDA (LTM) |
$ -82.9 M |
P/E (LTM) |
-3.608696 |
P/S (LTM) |
2.349145 |
EPS (LTM) |
-0.46 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
C4 Therapeutics
CCCC
|
$ 2.48 | -2.17 % | $ 206 M | Nasdaq Global Select Market | ||
|
Coherus BioSciences
CHRS
|
$ 0.41 | -14.71 % | $ 48 M | Nasdaq Global Market | ||
|
Celldex Therapeutics
CLDX
|
$ 27.63 | -1.46 % | $ 1.84 B | Nasdaq Global Select Market | ||
|
Cellectis S.A.
CLLS
|
$ 1.02 | -3.42 % | $ 102 M | Nasdaq Global Market | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.13 | 17.67 % | $ 113 M | NYSE American | ||
|
Edesa Biotech
EDSA
|
$ 2.07 | 5.61 % | $ 11.8 M | Nasdaq Capital Market | ||
|
Collegium Pharmaceutical
COLL
|
$ 26.02 | 1.84 % | $ 824 M | Nasdaq Global Select Market | ||
|
GlaxoSmithKline plc
GSK
|
$ 48.61 | -1.28 % | $ 197 B | NYSE | ||
|
CorMedix
CRMD
|
$ 4.51 | -3.53 % | $ 325 K | Nasdaq Global Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 40.19 | 0.09 % | $ 3.61 B | Nasdaq Global Market,SPB | ||
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | Nasdaq Capital Market | ||
|
Champions Oncology
CSBR
|
$ 4.59 | 0.04 % | $ 63.5 M | Nasdaq Capital Market | ||
|
Fennec Pharmaceuticals
FENC
|
$ 13.29 | -2.14 % | $ 380 M | Nasdaq Capital Market | ||
|
Cytokinetics, Incorporated
CYTK
|
$ 51.27 | -0.74 % | $ 6.16 M | Nasdaq Global Select Market,SPB | ||
|
Immunome
IMNM
|
$ 16.67 | -2.97 % | $ 1.46 B | Nasdaq Global Select Market | ||
|
Immunic
IMUX
|
$ 7.53 | 2.73 % | $ 1.17 B | Nasdaq Global Select Market | ||
|
Immunovant
IMVT
|
$ 33.18 | -0.09 % | $ 6.05 B | Nasdaq Global Select Market | ||
|
Incyte Corporation
INCY
|
$ 117.79 | -1.09 % | $ 23 B | Nasdaq Global Select Market,SPB | ||
|
Insmed Incorporated
INSM
|
$ 120.17 | -1.39 % | $ 23.9 B | Nasdaq Global Select Market | ||
|
Iovance Biotherapeutics
IOVA
|
$ 7.49 | -0.6 % | $ 2.68 M | Nasdaq Global Market,SPB | ||
|
Dyadic International
DYAI
|
$ 0.32 | 1.27 % | $ 11.6 M | Nasdaq Capital Market | ||
|
Ironwood Pharmaceuticals
IRWD
|
$ 4.79 | -1.75 % | $ 775 M | Nasdaq Global Select Market | ||
|
Fulcrum Therapeutics
FULC
|
$ 3.73 | -0.67 % | $ 284 M | Nasdaq Global Market | ||
|
Johnson & Johnson
JNJ
|
$ 272.65 | -2.17 % | $ 656 B | NYSE,SPB | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 94.99 | -0.13 % | $ 7.05 B | Nasdaq Global Select Market | ||
|
Kazia Therapeutics Limited
KZIA
|
$ 5.44 | 2.45 % | $ 82.9 M | Nasdaq Global Select Market | ||
|
Eli Lilly and Company
LLY
|
$ 1 381.41 | -2.41 % | $ 1.24 T | NYSE,SPB | ||
|
Immuron Limited
IMRN
|
$ 0.87 | -0.51 % | $ 201 M | Nasdaq Global Select Market | ||
|
Mesoblast Limited
MESO
|
$ 11.66 | -2.1 % | $ 14.1 B | Nasdaq Global Select Market | ||
|
Geron Corporation
GERN
|
$ 1.0 | -0.2 % | $ 667 M | Nasdaq Global Select Market | ||
|
Merck & Co.
MRK
|
$ 137.88 | -3.83 % | $ 345 B | NYSE,SPB | ||
|
Genmab A/S
GMAB
|
$ 50.93 | -1.98 % | $ 3.3 B | Nasdaq Global Select Market | ||
|
Moderna
MRNA
|
$ 196.67 | -4.9 % | $ 76.5 B | Nasdaq Global Select Market,SPB | ||
|
Gossamer Bio
GOSS
|
$ 11.37 | 2.99 % | $ 2.6 B | Nasdaq Global Select Market,SPB | ||
|
GeoVax Labs
GOVX
|
$ 1.99 | -1.24 % | $ 9.08 M | Nasdaq Global Select Market | ||
|
Grifols, S.A.
GRFS
|
$ 8.49 | -1.56 % | $ 5.77 B | Nasdaq Global Select Market | ||
|
Mirum Pharmaceuticals
MIRM
|
$ 92.52 | 0.62 % | $ 4.64 B | Nasdaq Global Select Market | ||
|
MediciNova
MNOV
|
$ 1.33 | -0.75 % | $ 65.3 M | Nasdaq Global Market | ||
|
InflaRx N.V.
IFRX
|
$ 1.11 | -3.48 % | $ 74.7 M | Nasdaq Global Select Market | ||
|
INmune Bio
INMB
|
$ 1.02 | 6.25 % | $ 25.3 M | Nasdaq Capital Market | ||
|
Ionis Pharmaceuticals
IONS
|
$ 27.39 | 1.59 % | $ 4.38 B | Nasdaq Global Select Market,SPB | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 246.57 | 2.43 % | $ 15 B | Nasdaq Global Select Market | ||
|
Nektar Therapeutics
NKTR
|
$ 34.77 | -3.17 % | $ 587 M | Nasdaq Global Select Market,SPB | ||
|
Kala Pharmaceuticals
KALA
|
$ 3.31 | -3.5 % | $ 27 M | Nasdaq Global Select Market | ||
|
Novartis AG
NVS
|
$ 155.26 | -2.43 % | $ 301 B | NYSE | ||
|
Omeros Corporation
OMER
|
$ 14.67 | 4.24 % | $ 932 M | Nasdaq Global Select Market | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.84 | 3.54 % | $ 193 M | NYSE American | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
$ 298.84 | 1.71 % | $ 5.78 B | Nasdaq Global Select Market,SPB | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.2 | 4.35 % | $ 54.8 M | Nasdaq Capital Market | ||
|
Mustang Bio
MBIO
|
$ 0.38 | -2.31 % | $ 1.87 M | Nasdaq Global Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.